LNP platforms

LNP-based nucleic acid drug delivery

Lipid nanoparticles (LNPs) act as advanced nanocarriers for nucleic acid delivery. They help protect the active payload from systemic degradation and deliver it to the intended site of action. By avoiding degradation and increasing delivery of their payload to the cytosol, LNPs enable more efficient & more effective nucleic acid therapeutics.

Customized LNP (cLNP) development

We believe that customized LNPs are critical enablers in advancing nucleic acid-based products to new levels of prophylactic and therapeutic utility. etherna has built expertise and implemented a suite of experimental approaches to customize LNPs for specific therapeutic applications. Additionally, etherna has advanced proprietary ionizable lipid libraries with different properties that we use to develop cLNPs. Our cLNP development capabilities are evidenced by our innovative and proprietary LNP platforms. We tailored those for specific routes of administration allowing better targeted biodistribution with an improved safety profile. Read below about some examples of cLNPs we have developed. With our expertise, suite of experimental tools, and proprietary ionizable lipid libraries, we support the development of LNPs customized for a specific payload and application.

Available LNP platforms

Cancer vaccines

Intra-tumoral (IT) administration

Maximized local mRNA expression in tumor
Reduced off-target expression in liver
Reduced reactogenicity and inflammation

Immuno-oncology

Intramuscular (IM) administ

Utilize novel ionizable lipids in proprietary constructs to maximize local mRNA expression
These formulations also show good tolerability and safety, with very low local reactogenicity

Prophylactic vaccines

Intramuscular (IM) administr

Utilize novel ionizable lipids in proprietary constructs to maximize local mRNA expression
These formulations also show good tolerability and safety, with very low local reactogenicity

Auto-immune diseases

Induction of immune tolerance against auto-antigen

Liver diseases, secreted factors

High expression in liver after intravenous administration

Our strengths

Comprehensive
Our different families of LNP formulations cover different therapeutic applications, such as prophylactic and cancer vaccines, gene therapy, protein replacement, etc.

Customizable
With our expertise, suite of experimental tools, and proprietary ionizable lipid libraries, we support the development of LNPs customized for a specific payload and application.

World Class facilities
Our world-class LNP manufacturing facilities in Ghent & Niel, Belgium, support the production of LNPs for any preclinical project and scale up the LNP production to a GMP-ready stage.